Lizzie Marie Ramos Tollinchi

Mrs. Lizzie Marie Ramos Tollinchi

University of Puerto Rico, Medical Sciences Campus, San Juan, Texas, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
PLPaola Lopez-Marte
Paola Lopez-Marte
ASAlondra Soto-González
Alondra Soto-González
LTLizzie Marie Ramos Tollinchi
Lizzie Marie Ramos Tollinchi
STStephan J Torres
Stephan J Torres
MFMariana Ferre
Mariana Ferre
CSCarlos A. Sariol
Carlos A. Sariol
Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity.

29 June 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
PLPaola López-Marte
Paola López-Marte
ASAlondra Soto-González
Alondra Soto-González
LTLizzie Marie Ramos Tollinchi
Lizzie Marie Ramos Tollinchi
STStephan J Torres
Stephan J Torres
MFMariana Ferre
Mariana Ferre
CSCarlos A. Sariol
Carlos A. Sariol
Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine's effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose has the capacity to neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)].56 su bjects with IBD and 12 healthy subjects were recruited. 90% of patients with IBD (49/56) were receiving biologics and/or immunomodulatory therapy. 24 subjects with IBD did not develop effective neutralizing capability against the Omicron variant. 70% (17/24) of those subjects were receiving anti-Tumor Necrosis Factor therapy [10= adalimumab, 7= infliximab], two of them had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and larger studies are needed to evaluate optimal immunity.

14 August 2026 in JCC Plus
Verified
Journal Article
Open access
PDF file
ASAlondra Soto‐González
Alondra Soto‐González
LTLizzie Marie Ramos Tollinchi
Lizzie Marie Ramos Tollinchi
CAClaudia P Amaya-Ardila
Claudia P Amaya-Ardila
PLPaola López‐Marte
Paola López‐Marte
ASAndrea Sánchez‐Velázquez
Andrea Sánchez‐Velázquez
ETEsther Torres
Esther Torres
Background and Aims: The limited data on ethnic minorities with inflammatory bowel disease (IBD) is a growing concern, given its increasing incidence in Hispanics in the United States and Latin America. Our aim was to describe a large cohort of Hispanics with IBD studied over two decades. Methods: The University of Puerto Rico IBD Registry has been recruiting patients since 1995. We describe a cohort of Hispanic patients recruited from 1995 through 2020, compared by time period (1995–2009 vs. 2010–2020) and diagnosis. The variables included sex, age, age at the onset of symptoms, IBD diagnosis, disease extent, family history of IBD, smoking history, extraintestinal manifestations, medications, and history of surgery for IBD. Descriptive statistics included frequencies, medians, means, and standard deviations. Results: We included 1365 Hispanic patients; 845 (62%) had Crohn's disease (CD), 520 (38%) had ulcerative colitis, and 710 (52%) were male. Compared with the 1995–2009 cohort, the proportion of CD diagnoses increased significantly in 2010–2020 (53.7%–68.1%; p < 0.001). Use of anti‐tumor necrosis factor (anti‐TNF) agents rose markedly from 10.2% to 58.4% and immunomodulators from 18.2% to 32.1% (both p < 0.001), while aminosalycylates and corticosteroids declined ( p < 0.001). Corticosteroids and antibiotics use remained stable with no significant change. Overall extraintestinal manifestation decreased from 36.3% to 25.5% ( p < 0.001) and family history of IBD increased in both diagnostic groups. IBD‐related surgery rate remained stable. For CD cases, the disease extent changed significantly between the two time cohorts, with most cases having ileocolonic (38.3% vs. 46.9%) or ileal (36.7% vs. 33.9%) inflammation. Perianal disease decreased from 26.7% to 16.8%. CD disease behavior showed significant change, 62.4% of CD cases had a penetrating disease (83.0% vs. 52.1%), 24.8% stricturing (13.8% vs. 30.3%), and 12.8% non‐stricturing/non‐penetrating (3.2% vs. 17.6%). UC disease extent (480/528) showed no significant difference with the majority of cases having pancolitis (51.6% vs. 53.0) or left‐sided colitis (21.0% vs. 21.4) in both time cohorts ( p = 0.481). Conclusions: Differences over time may reflect changes in disease phenotypes, environmental influences, the impact of physician awareness and healthcare access, and/or new management guidelines and therapies. Temporal trends should be interpreted cautiously in light of Puerto Rico's aging population and substantial out‐migration. The increase in IBD in Hispanics in the US and Latin America warrants further studies to better characterize this population, explore outcomes, and define ethnic differences and disparities in this cohort.